A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet®/Daivobet®/Taclonex®) in the treatment of psoriasis vulgaris

British Journal of Dermatology

Volumn 154, Issue 6, 2006, Pages 1155-1160

  Kragballe, K ^a   Austad, J ^b   Barnes, L ^c   Bibby, A ^d   De La Brassinne, M ^e   Cambazard, F ^f   Fleming, C ^g   Heikkila H ^h   Jolliffe, D ^d   Peyri, J ⁱ   Svensson, A ^j   Toole, J ^k   Wozel, G ^l  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Hudlegekontoret   (Norway)

^c ST JAMES S HOSPITAL   (Ireland)

^d Leo Pharmaceuticals   (United Kingdom)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f HÔPITAL NORD   (France)

^g PERTH ROYAL INFIRMARY   (United Kingdom)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j LUND UNIVERSITY HOSPITAL   (Sweden)

^k Dermadvances Research   (Canada)

^l UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

more..

Author keywords

Betamethasone dipropionate; Calcipotriol; Psoriasis; Randomized controlled trial; Safety; Two compound product

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CORTICOSTEROID; TACLONEX;

ADRENAL INSUFFICIENCY; ADULT; AGED; ARTICLE; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPIGMENTATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FEMALE; FOLLICULITIS; FURUNCULOSIS; HUMAN; HYPERTRICHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; PURPURA; PUS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN ATROPHY; SKIN PAPILLOMA; STRIA;

ADULT; BETAMETHASONE; CALCITRIOL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 33646590026     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07236.x     Document Type: Article

References (12)

1. Greaves MW Weinstein GP Treatment of psoriasis N Engl J Med 1995 332 581 8
2. Finlay AY Coles EC The effect of severe psoriasis on the quality of life of 369 patients Br J Dermatol 1995 132 236 44
3. TM) is an effective once-daily treatment for psoriasis vulgaris Dermatology 2002 205 389 93
4. Papp KA Guenther L Boyden B et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis J Am Acad Dermatol 2003 48 48 54
5. Douglas WS Poulin Y Decroix J et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris Acta Derm Venereol 2002 82 131 5
6. Kragballe K Noerrelund KL Lui H et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris Br J Dermatol 2004 150 1167 73
7. Ashcroft DM Li Wan Po A Griffiths CEM Therapeutic strategies for psoriasis J Clin Pharm Ther 2000 25 1 10
8. Ramsay CA Berth-Jones J Brundin G et al. Long-term use of topical calcipotriol in chronic plaque psoriasis Dermatology 1994 189 260 4
9. Poyner T Hughes JW Dass BK et al. Long term use of topical calcipotriol in chronic plaque psoriasis J Dermatolog Treat 1993 4 173 7
10. Ellis JP Griffiths WAD Klaber MR Long-term treatment of chronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short contact dithranol Eur J Clin Res 1995 7 247 57
11. Gawkrodger DJ on behalf of the Therapy Guidelines and Audit Subcommittee of the British Association of Dermatologists Current management of psoriasis J Dermatolog Treat 1997 8 27 55
12. International Conference on Harmonisation, Harmonised Tripartite Guideline The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions: E1 ()